PALO
ALTO, Calif., Oct. 11,
2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq:
KOD), a biopharmaceutical company committed to researching,
developing and commercializing transformative therapeutics to treat
high prevalence retinal diseases, announced today that three
scientific presentations on tarcocimab tedromer (KSI-301),
including a first-time presentation of the primary results from the
Phase 3 DAYLIGHT study in wet age-related macular degeneration
(AMD), a first-time presentation of the Year 1 head-to-head results
from the Phase 3 BEACON study in retinal vein occlusion (RVO), and
the primary results and new analyses from the Phase 3 GLEAM and
GLIMMER studies in diabetic macular edema (DME), will be shared at
the 56th Annual Scientific Meeting of The Retina
Society, being held from Oct 11 – 14
in New York, United States.
"At the Retina Society meeting, data will be presented across
four pivotal trials for tarcocimab and will include the results of
recent investigations on the higher cataract incidence in patients
with DME and the implications of our ongoing findings on the
development of our ABC Platform derived medicines," said
Victor Perlroth, M.D., Chief
Executive Officer of Kodiak Sciences.
The following will be presented at the meeting by our clinical
investigators:
Title: Tarcocimab tedromer (KSI-301) 5 mg for the
treatment of wAMD: One-year primary efficacy,durability, and
safety outcomes of the Phase 3 DAYLIGHT Study
Presentation
Date and Time: October 13, 2023;
8:52 AM ET
Presenter: Brandon Busbee, M.D.,
Tennessee Retina and Retina Consultants of America
Title: Tarcocimab tedromer (KSI-301) Anti-VEGF Antibody
Biopolymer Conjugate for Diabetic Macular Edema: Primary Endpoint
Efficacy and Safety Outcomes of the GLEAM and GLIMMER Phase 3
Pivotal Studies
Presentation Date and Time: October 13, 2023; 10:28 AM
ET
Presenter: Robert Wong, M.D., FASRS,
Austin Retina Associates
Title: Tarcocimab tedromer (KSI-301) 5 mg for the
treatment of RVO: One-year primary efficacy, durability, and
safety outcomes of the Phase 3 BEACON Study
Presentation
Date and Time: October 13, 2023;
10:38 AM ET
Presenter: Ankoor Shah, M.D., Retina
Consultants of Texas
Kodiak plans to post the presentation slides on the "Events and
Presentations" section of Kodiak's website at http://ir.kodiak.com/
at the beginning of each presentation.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to
researching, developing and commercializing transformative
therapeutics to treat high-prevalence retinal diseases. We are
focused on bringing new science to the design and manufacture of
next generation retinal medicines to prevent and treat the leading
causes of blindness globally. Our antibody biopolymer conjugate
platform, or ABC Platform™ is at the core of Kodiak's discovery
engine. Kodiak's first investigational medicine, tarcocimab
tedromer, is a novel anti-VEGF antibody biopolymer conjugate
explored for the treatment of retinal vascular diseases. Kodiak's
second clinical program, KSI-501, built from a first-in-class
bispecific protein targeting both IL-6 (anti-IL-6 antibody) and
VEGF (VEGF-trap), is intended to treat both orphan and high
prevalence retinal diseases. Kodiak is based in Palo Alto, CA. For more information, please
visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak
logo are registered trademarks or trademarks of Kodiak Sciences
Inc. in various global jurisdictions.
View original
content:https://www.prnewswire.com/news-releases/kodiak-sciences-announces-upcoming-presentations-at-the-56th-annual-scientific-meeting-of-the-retina-society-301953169.html
SOURCE Kodiak Sciences Inc.